Comparison of MR-less PiB SUVR quantification methods

Neurobiology of Aging

Volumn 36, Issue S1, 2015, Pages S159-S166

  Bourgeat, Pierrick ^a   Villemagne, Victor L ^b,c   Dore, Vincent ^a,c   Brown, Belinda ^d   Macaulay, S Lance ^a   Martins, Ralph ^d   Masters, Colin L ^b   Ames, David ^b   Ellis, Kathryn ^b   Rowe, Christopher C ^c   Salvado, Olivier ^a   Fripp, Jurgen ^a  

^a CSIRO   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c AUSTIN HEALTH   (Australia)

^d EDITH COWAN UNIVERSITY   (Australia)

Author keywords

Alzheimer's disease; PET quantification; Pittsburgh compound B

Indexed keywords

AMYLOID BETA PROTEIN; CARBON 11; PITTSBURGH COMPOUND B; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BIOLOGICAL MARKERS; THIAZOLES;

ACCURACY; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; CORRELATION ANALYSIS; DISEASE MARKER; GRAY MATTER; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MEASUREMENT ERROR; NEOCORTEX; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; RADIOLOGICAL PARAMETERS; STANDARDIZED UPTAKE VALUE RATIO; THREE DIMENSIONAL IMAGING; COMPARATIVE STUDY; DIAGNOSTIC USE; HUMANS; MAGNETIC RESONANCE IMAGING; METABOLISM; METHODS; NEUROIMAGING; PATHOLOGY; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; RADIONUCLIDE IMAGING;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BIOLOGICAL MARKERS; GRAY MATTER; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROIMAGING; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; THIAZOLES;

EID: 84916620385     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.04.033     Document Type: Article

References (33)

1. Aljabar P., Heckemann R., Hammers A., Hajnal J., Rueckert D. Multi-atlas based segmentation of brain images: atlas selection and its effect on accuracy. Neuroimage 2009, 46:726-738.
2. Bland J., Altman D. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 1:307-310.
3. Bourgeat, P., Dore, V., Shen, K.-K., Raniga, P., Salvado, O., Fripp, J., the Alzheimer's Disease Neuroimaging Initiative. 2012a. Atrophy challenge: enforcing longitudinal consistency in longitudinal analysis using multi-atlas segmentation. In MICCAI 2012 Workshop on Novel Imaging Biomarkers for Alzheimer's Disease and Related Disorders (NIBAD'12), Nice, France, October5.
4. Bourgeat, P., Raniga, P., Dore, V., Zhou, L., Macaulay, S.L., Martins, R., Masters, C., Ames, D., Ellis, K.A., Villemagne, V., Rowe, C., Salvado, O., Fripp, J., on behalf of the AIBL Research Group. 2012b. Manifold driven MR-less PiB SUVR normalisation. In MICCAI 2012 Workshop on Novel Imaging Biomarkers for Alzheimer's Disease and Related Disorders (NIBAD'12), Nice, France, October5.
5. Edison P., Carter S., Rinne J.O., Gelosa G., Herholz K., Nordberg A., Brooks D.J., Hinz R. Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET. Neuroimage 2013, 70:423-433.
6. Ellis K.A., Bush A.I., Darby D., De Fazio D., Foster J., Hudson P., Lautenschlager N.T., Lenzo N., Martins R.N., Maruff P. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int. Psychogeriatr. 2009, 21:672-687.
7. Fripp J., Bourgeat P., Acosta O., Raniga P., Modat M., Pike K.E., Jones G., O'Keefe G., Masters C.L., Ames D., Ellis K.A., Maruff P., Currie J., Villemagne V.L., Rowe C.C., Salvado O., Ourselin S. Appearance modeling of 11C PiB PET images: characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging. Neuroimage 2008, 43:430-439.
8. Fripp J., Bourgeat P., Raniga P., Acosta O., Villemagne V., Jones G., O'keefe G., Rowe C., Ourselin S., Salvado O. MR-less high dimensional spatial normalization of 11C PiB PET images on a population of elderly, mild cognitive impaired and Alzheimer disease patients. Med. Image Comput. Comput. Assist. Interv. 2008, 11(Pt 1):442-449.
9. Ishii K., Willoch F., Minoshima S., Drzezga A., Ficaro E.P., Cross D.J., Kuhl D.E., Schwaiger M. Statistical brain mapping of 18F-FDG PET in Alzheimer's disease: validation of anatomic standardization for atrophied brains. J.Nucl. Med. 2001, 42:548-557.
10. Jack C.R., Lowe V.J., Senjem M.L., Weigand S.D., Kemp B.J., Shiung M.M., Knopman D.S., Boeve B.F., Klunk W.E., Mathis C.A., Petersen R.C. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008, 131(Pt 3):665-680.
11. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergström M., Savitcheva I., Huang G., Estrada S., Ausén B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., Långström B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 2004, 55:306-319.
12. Lopresti B.J., Klunk W.E., Mathis C.A., Hoge J.A., Ziolko S.K., Lu X., Meltzer C.C., Schimmel K., Tsopelas N.D., DeKosky S.T. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J.Nucl. Med. 2005, 46:1959-1972.
13. Masters C.L., Beyreuther K. Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Aβ amyloid pathway. Brain 2006, 129(Pt 11):2823-2839.
14. Matsunari I., Samuraki M., Chen W., Yanase D., Takeda N., Ono K., Yoshita M., Matsuda H., Yamada M., Kinuya S. Comparison of 18F-FDG PET and optimized voxel-based morphometry for detection of Alzheimer's disease: aging effect on diagnostic performance. J.Nucl. Med. 2007, 48:1961-1970.
15. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
16. Minoshima S., Frey K.A., Koeppe R.A., Foster N.L., Kuhl D.E. Adiagnostic approach in Alzheimer's disease using three-dimensional Stereotactic Surface Projections of Fluorine-18-FDG PET. J.Nucl. Med. 1995, 36:1238-1248.
17. Modat M., Ridgway G.R., Taylor Z.A., Lehmann M., Barnes J., Hawkes D.J., Fox N.C., Ourselin S. Fast free-form deformation using graphics processing units. Comput. Methods Programs Biomed. 2010, 98:278-284.
18. Ourselin S., Roche A., Subsol G., Pennec X., Ayache N. Reconstructing a 3D structure from serial histological sections. Image Vis. Comput. 2001, 19:25-31.
19. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 1999, 56:303-308.
20. Powell M.J.D. An efficient method for finding the minimum of a function of several variables without calculating derivatives. Comput. J. 1964, 7:155-162.
21. Raniga P., Bourgeat P., Villemagne V., O'Keefe G., Rowe C., Ourselin S. Spline based inhomogeneity correction for 11C-PIB PET segmentation using expectation maximization. Med. Image Comput. Comput. Assist. Interv. 2007, 10(Pt 1):228-235.
22. Rohlfing T., Rademacher M.H., Pfefferbaum A. Volume reconstruction by inverse interpolation: application to interleaved MR motion correction. Med. Image Comput. Comput. Assist. Interv. 2008, 11(Pt 1):798-806.
23. Rowe C.C., Ackerman U., Browne W., Mulligan R., Pike K.L., O'Keefe G., Tochon-Danguy H., Chan G., Berlangieri S.U., Jones G. Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008, 7:129-135.
24. Rowe C.C., Ellis K.A., Rimajova M., Bourgeat P., Pike K.E., Jones G., Fripp J., Tochon-Danguy H., Morandeau L., O'Keefe G. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging 2010, 31:1275-1283.
25. Schneider J.A., Arvanitakis Z., Leurgans S.E., Bennett D.A. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann. Neurol. 2009, 66:200-208.
26. Schmahmann J.D., Doyon J., McDonald D., Holmes C., Lavoie K., Hurwitz A.S., Kabani N., Toga A., Evans A., Petrides M. Three-dimensional MRI atlas of the human cerebellum in proportional stereotaxic space. Neuroimage 1999, 10(3Pt1):233-260.
27. Tustison N.J., Avants B.B., Cook P.A., Zheng Y., Egan A., Yushkevich P.A., Gee J.C. N4ITK: improved N3 bias correction. IEEE Trans. Med. Imaging 2010, 29:1310-1320.
28. Tzourio-Mazoyer N., Landeau B., Papathanassiou D., Crivello F., Etard O., Delcroix N., Mazoyer B., Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002, 15:273-289.
29. Van Leemput K., Maes F., Vandermeulen D., Suetens P. Automated model-based tissue classification of MR images of the brain. IEEE Trans. Med. Imaging 1999, 18:897-908.
30. Vandenberghe R., Van Laere K., Ivanoiu A., Salmon E., Bastin C., Triau E., Hasselbalch S., Law I., Andersen A., Korner A., Minthon L., Garraux G., Nelissen N., Bormans G., Buckley C., Owenius R., Thurfjell L., Farrar G., Brooks D.J. 18F-flutemetamol amyloid imaging in Alzheimer diseaseand mild cognitive impairment: a phase 2 trial. Ann. Neurol. 2010, 68:319-329.
31. Villemagne V.L., Pike K.E., Chételat G., Ellis K.A., Mulligan R.S., Bourgeat P., Ackermann U., Jones G., Szoeke C., Salvado O., Martins R., O'Keefe G., Mathis C.A., Klunk W.E., Ames D., Masters C.L., Rowe C.C. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann. Neurol. 2011, 69:181-192.
32. Wolz R., Aljabar P., Hajnal J.V., Hammers A., Rueckert D. LEAP: learning embeddings for atlas propagation. Neuroimage 2010, 49:1316-1325. Alzheimer's Disease Neuroimaging Initiative.
33. Wong D.F., Rosenberg P.B., Zhou Y., Kumar A., Raymont V., Ravert H.T., Dannals R.F., Nandi A., Brašić J.R., Ye W. Invivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (flobetapir F 18). J.Nucl. Med. 2010, 51:913-920.